Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASH 2024 Insights: Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma : Episode 1
Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies
Robert M. Rifkin, MD, FACP, discusses how findings from real-world studies on teclistamab and talquetamab presented at the 66th American Society of Hematology Annual Meeting and Exposition reinforce their efficacy and impact on patient outcomes in relapsed/refractory multiple myeloma while panelists discuss how clinicians should prioritize factors such as patient characteristics and treatment history when selecting the most appropriate bispecific therapy for these patients.
Video content above is prompted by the following:
- Findings from real-world studies on teclistamab and talquetamab presented at 66th American Society of Hematology Annual Meeting and Exposition highlighted their efficacy and patient outcomes outside clinical trials. How do these findings align with clinical trial data, and what differences (if any) stand out to you in the real-world setting?
- Based on the real-world evidence shared for teclistamab and talquetamab, what factors should clinicians prioritize when selecting the appropriate bispecific therapy for patients with relapsed/refractory multiple myeloma?
Related Videos
Related Content
